Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New blood test could reveal hidden COVID-19 infections

NCT ID NCT04418206

Knowledge-focused Sponsor: Centre Hospitalier Universitaire de Nice Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a blood test called ELISpot to see if it can detect the body's immune response to the COVID-19 virus. The test aims to find infections that standard swab tests might miss and help predict whether a person will develop mild or severe illness. Researchers enrolled 950 people, including those with confirmed or suspected COVID-19, their close contacts, and healthy volunteers.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this test could help doctors better understand when someone was infected and predict whether they might develop severe COVID-19.
What could go wrong
This is an observational study, not a treatment trial. The test may not prove accurate enough for widespread use, and results may not change patient care directly.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

950 people

The number who actually took part.

Started

Jun 2020

Finished

Jul 2022

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * age ≥ 18 years, * patients with confirmed SARS-Cov2 infection (RT PCR positive) * or patients suspected (evocative chest scanner) * OR patients exposure to SARS-CoV2 but no symptoms (patient's family, caregivers) * OR patients Non exposure to SARS-Cov2 volunteer subjects (general population) Exclusion Criteria: * pregnant or breastfeeding female

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COVID-19 are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

COVID-19

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COVID-19

Contacts and locations

Locations

  • CH Antibes

    Antibes, Alpes Maritimes, 06606, France

  • CHU de nice

    Nice, Alpes-Maritimes, 06001, France

  • Ch Cannes, Pneumologie

    Cannes, Alpes Maritimes, 06414, France

  • Ch Grasse

    Grasse, Alpes Maritimes, 06355, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.